StockData
Veradermics, Inc logo

Veradermics, Inc (MANE) stock

MANENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$129.66−5.63 (-4.16%)

Close on Nov 13, 2026Market cap $5.42BP/E –Yield –

Earnings

Veradermics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 29, 2027
Q4 FY2026 · estimated, before the open
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Veradermics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 29, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026before the open–––Release
Q2 FY2026ended Jun 30, 2026Aug 11, 2026before the open–––Release
Q1 FY2026ended Mar 31, 2026May 12, 2026before the open–––Release
Q4 FY2025ended Dec 31, 2025Mar 30, 2026before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Veradermics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Veradermics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Veradermics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
    Results
  2. Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss
    Update
  3. Study ‘302’ Part B Phase 3 Topline Data in Males with Mild-to-Moderate Pattern Hair Loss November 2026 NOVEMBER 2026
    Update
  4. Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in
    Update
  5. Study ‘304’ Part A Phase 3 Topline Data in Males with Mild-to-Moderate Pattern Hair Loss October 2026 OCTOBER 2026
    Update
  6. Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
    Results
  7. Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout
    Update
  8. Study ‘207’ Phase 2 Topline Open Label Data in Females with Mild-to-Moderate Pattern Hair Loss July 2026
    Update
  9. Veradermics Reports First Quarter 2026 Financial Results and
    Results
  10. Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss
    Update
  11. Study 302 Phase 2/3 Topline Data in Males with Mild-to-Moderate Pattern Hair Loss April 2026
    Update
  12. Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates
    Results

See a number that looks wrong?